Shopping Cart
- Remove All
Your shopping cart is currently empty
Cendakimab (RPC4046) is a humanized monoclonal antibody targeting IL-13. It selectively targets the IL-13 receptor (IL13R-α1 and IL13R-α2), used in research on atopic dermatitis.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $163 | In Stock | |
| 5 mg | $463 | In Stock | |
| 10 mg | $742 | In Stock | |
| 25 mg | $1,120 | In Stock | |
| 50 mg | $1,490 | In Stock |
| Description | Cendakimab (RPC4046) is a humanized monoclonal antibody targeting IL-13. It selectively targets the IL-13 receptor (IL13R-α1 and IL13R-α2), used in research on atopic dermatitis. |
| Targets&IC50 | IL-13Rα1:352 pM, IL-13α2:631 pM, glycosylated IL-13:37 pM, aglycosylated IL-13:17 pM |
| In vitro | Cendakimab is an IgG1k humanized monoclonal antibody that recognizes IL-13 and inhibits its binding to IL-13 receptor-specific subtypes (IL-13-Rα1 and IL-13-Rα2) with an IC50 of 352 pM and 631 pM, respectively, as determined by ELISA. [2] cendakimab inhibited glycosylated and non-glycosylated IL-13-induced STAT6 activity in a dose-dependent manner with IC50 of 37pM and 17pM, respectively. [1] |
| In vivo | In a mouse model of asthma, Cendakimab dose-dependent inhibited AHR (maximum inhibition 70.5%) and IL-13-dependent gene expression, and maximal inhibition of Muc5ac and AMCase activity was 70.7% and 54.2%, respectively. [2] |
| Synonyms | RPC4046, RPC 4046, CC93538, CC 93538, ABT-308, ABT308 |
| Cas No. | 2151032-62-9 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.